ATXI

0.30000.00%
AM

Alexandra MacLean

CEO & Director

Dr. Alexandra MacLean, also known as Alix, MD, serves as Director of Kent Imaging Inc. since January 2021. She is Chief Executive Officer at Avenue Therapeutics, Inc. since August 01, 2022 and serves as its Director since March 07, 2023. She previously served as Entrepreneur in Residence at Fortress, a biopharmaceutical company and a partner company of Avenue Therapeutics, from November 2021 through July 2022. She served as a Senior Advisor at TVM Life Science Management Inc. since 2021. She served as a Principal at TVM Life Science Management Inc from 2020 to 2021. She joined TVM Life Science Management Inc in 2020. She is employed at Covidien Energy-based Devices. Dr. MacLean served as a Director at Access Vascular, Inc. since March 2021. Dr. MacLean joined Covidien in June 2010 as the Medical Director with a focus on upstream assessments, disruptive technologies and business development and licensing. She took on the role of Vice President Global Medical Affairs in October 2011. In September 2012, she moved to a corporate medical affairs function where she works closely with Covidien Ventures, Business Development and Licensing and Strategy. Prior to joining Purdue, she served at Plasma Surgical, Inc. a medical device company, from 2014 to 2015 and Covidien, a medical devices and supplies manufacturer later acquired by Medtronic plc (NYSE: MDT), from 2010 to 2013. Prior to Covidien, Dr. Maclean worked at Merck & Co. in cardiovascular drug development leading Phase IIA through V clinical trials. Dr. Maclean is a Member of the Council of Advisors of Bioinspire. Dr. MacLean had been Principal at TVM Capital GmbH since January 2020 until October 2021. She joined the firm in 2020. She serves as a Director of Kent Imaging Inc. She received a bachelor of science degree in Physiology from McGill University and a MD degree from Columbia University. She also holds a MPhil from Cambridge University and an MBA from the Leeds School of Business at the University of Colorado, Boulder. She also serves as Head of Licensing and Business Development at Imbrium Therapeutics L.P. a clinical-stage biopharmaceutical company and a subsidiary of Purdue Pharma, L.P. (“Purdue”), from January 2019 through January 2020.

Positions